uniQure (Nasdaq: QURE) will advance AMT-061 into a pivotal study in 2018 for patients with severe and moderately severe hemophilia B. Shares of the biopharmaceutical leaped $5.69 to close at $15.16.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.